A 62-year-old woman with acute promyelocytic leukaemia was treated with all-trans retinoic acid. On day 2 she suffered with dyspnoea and general fatigue. Marked hypoxia suggested the occurrence of retinoic acid syndrome. She underwent endotracheal intubation and mechanical ventilation with the administration of dexamethasone. Her symptoms promptly abated. She was subsequently treated with conventional chemotherapy and achieved complete remission.
All-trans retinoic acid (ATRA) has been used successfully in treating patients with acute promyelocytic leukaemia. Its overall toxicity is considerably less compared to standard chemotherapy: however, 25 to 30% of patients develop a potentially fatal symptom complex known as retinoic acid syndrome 1 . This syndrome is characterized by fever, dyspnoea, acute respiratory distress, pulmonary infiltrates, pleural effusions, hyperleucocytosis, hypotension and hepatic, renal and multi-organ failure. Experience has shown that early corticosteroid therapy significantly reduces the mortality from this complication.
We report a case of a patient with the classical features of the syndrome who required mechanical ventilation of her lungs for respiratory failure but whose condition dramatically improved following steroid treatment.
CASE REPORT
A 62-year-old woman gave a brief history of anorexia, tiredness and generally feeling unwell. A full blood count taken by her general practitioner subsequently led to a diagnosis of acute promyelocytic leukaemia. Her past medical history was of mild hypertension for which she took a diuretic. She had no allergies.
On admission, she was pyrexial with spontaneous bleeding from her gums. Her chest examination was unremarkable. Haematology showed haemoglobin 7.2 g/dl (range 11.5 to 16.0 g/dl), WCC 2.9x10 9 /l (range 4.0 to 11.0x10 9 /l), and platelets 29x10 9 /l (range 150 to 400x10 9 /l). Coagulation studies were INR 1.4 (range 1 to 1.1), fibrinogen 1.7 g/dl (range 2 to 4 g/dl), and D-Dimer 8.0 mg/l (normal <1 mg/l).
She was commenced on ATRA and antibiotics, and given blood products for the coagulopathy.
Two days into her treatment she became dyspnoeic and looked cyanosed. Arterial blood gases on air showed pH 7.52, PO 2 6.6 kPa and PCO 2 4.5 kPa. Chest examination revealed diffuse bilateral crepitations. The chest X-ray report read as symmetrical, poorly defined nodular shadowing, confluent in areas, with relative sparing of the lung apices ( Figure 1 ). Retinoic acid syndrome was diagnosed. ATRA was stopped and conventional chemotherapy commenced. Dexamethasone 10 mg intravenously every 12 hours was started. Her condition continued to deteriorate and she was admitted to the intensive care unit the same day. Her trachea was intubated and mechanical ventilatory support was instituted. Initial oxygen requirements were high-the P a O 2 was 9.6 kPa with an inspired oxygen concentration of 60% and a PEEP level of 5 cmH 2 O. The insertion of a pulmonary artery catheter revealed a PAOP of 16 mmHg and a cardiac index of 3.0 l/min/m 2 . Dobutamine was commenced at an initial dose of 6 µg/kg/min. There was also a mild degree of renal dysfunction evidenced by a raised urea (maximum level 12.6 mmol/l) and a creatinine clearance of 52 ml/min as measured by a 24-hour urine collection.
Over the next three days her condition dramatically improved. The ventilatory support was weaned and her trachea was extubated on day 3. She returned to the ward five days after her initial admission to the intensive care unit. Arterial blood gases prior to discharge were PO 2 10.2 kPa and PCO 2 5.0 kPa with 3 l/min O 2 via nasal speculum. A reducing dose of dexamethasone was prescribed.
During her subsequent hospital stay, she continued to receive conventional chemotherapy and several courses of antibiotics. Her progress was interrupted by an episode of Clostridium difficile colitis and by the development of a left subclavian vein thrombosis related to her Hickman line.
Three years after the diagnosis of acute promyelocytic leukaemia she is asymptomatic and remains in remission.
DISCUSSION
All-trans retinoic acid, a vitamin A derivative, is a potent differentiation agent that is effective therapy for acute promyelocytic leukaemia. Patients treated with ATRA and chemotherapy have been shown to have a better outcome than those treated with conventional chemotherapy alone 2 . Numerous studies have confirmed that the majority of patients achieve complete remission with ATRA. In addition, the characteristic life-threatening coagulopathy resolves quickly 3 .
The clinical features of retinoic acid syndrome are characterized by fever, dyspnoea, effusions, weight gain and organ failure. Larrea et al 4 reported a case associated with cardiac tamponade due to massive pericardial effusion. Other less common features include cutaneous nodules, intracranial hypertension 5 and cardiac conduction defects. Pulmonary computed tomography classically shows pleural effusions with small, irregular, peripheral nodules in the lung fields 6 .
The cause of retinoic acid syndrome is unknown. The enhanced production and release of vasoactive cytokines from leukaemic cells, the increased expression of adhesion molecules on myeloid cell surfaces and the acquisition of migratory properties of leukaemic cells undergoing differentiation are proposed as possible mechanisms 7, 8 . Post mortem studies have shown extensive organ infiltration by leukaemic cells.
The administration of high-dose corticosteroid therapy early in the course of the syndrome can result in prompt symptomatic improvement and full recovery in a significant number of patients 9 . Larson et al 7 have shown that methylprednisolone therapy rapidly inhibits acute promyelocytic leukaemia cell aggregation, thus reversing the proposed cause of the syndrome. This contrasts with the current opinion regarding the use of steroids in the acute respiratory distress syndrome (ARDS), a condition with multiple aetiologies associated with a similar picture of diffuse pulmonary alveolar infiltrates and interstitial fibrosis. Administration of steroids to prevent or halt the progression of ARDS has been largely ineffective 10 , although their use for the fibroproliferative phase of ARDS may have promise 11, 12 .
In this particular case, a PAOP of 16 mmHg raises the suspicion of acute left ventricular failure. However, the PAOP can be very unreliable in acute lung injury and the clinical course of our patient suggested that left ventricular failure was unlikely. The inotrope requirements were minimal, there was no radiological evidence, and the fact that the patient was discharged from the intensive care unit without the need for diuretics or heart failure medication opposed a diagnosis of left ventricular failure.
Steroids can be used as part of the treatment regimen of various types of leukaemia and it has been suggested that combining steroids with ATRA from the outset may influence the development of retinoic acid syndrome. Unfortunately, steroids are not standard treatment for acute promyelocytic leukaemia and their use, aside from cases that develop the syndrome, is associated with a significant incidence of life-threatening fungal infections.
Given the success of ATRA in acute promyelocytic leukaemia, studies in other haematological and nonhaematological malignancies are being conducted and we may well see a wider spectrum of activity for the retinoid-based drugs. Indeed, early studies have shown that if children with neuroblastoma are given a related drug, 13-cis retinoic acid, it doubles the number who are cured after standard therapy 13 . This will have the effect of producing an expanding population of patients with various malignancies that subsequently require intensive care support due to the development of the retinoic acid syndrome. Early recognition of the symptom complex of fever and dyspnoea, combined with prompt corticosteroid treatment, may decrease morbidity and mortality associated with this syndrome.
